Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...
Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and ...
Rigel Pharmaceuticals Gets FDA Orphan-Drug Designation for R289
Rigel Pharmaceuticals on Thursday said the U.S. Food and Drug Administration granted orphan-drug designation to its proposed R289 treatment for myelodysplastic syndromes, a group of rare blood cancers ...
Rigel announces R289 granted Orphan Drug designation by FDA for MDS
Rigel Pharmaceuticals (RIGL) announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to R289 for the treatment ...
Rigel Pharmaceuticals, Inc.: Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that the U.S. Food and Drug Administration (FDA) has ...
Rigel Pharma: FDA Grants Orphan Drug Designation To R289 - Quick Facts
Rigel Pharmaceuticals (RIGL) announced the FDA has granted Orphan Drug designation to R289 for the treatment of myelodysplastic ...
Zacks.com on MSN1d
Small-Cap Stocks Can Outperform Large-Cap Peers in 2025: 5 Top Picks
U.S. stock markets witnessed an impressive rally in 2024 after an astonishing bull run in 2023. Following the 24.2% ascent in ...
pharmaphorum3d
Chinese biotech Sironax raises $200m for RIPK1 pipeline
Rigel Pharmaceuticals meanwhile has completed a phase 1 programme for R552 and last year partnered with Eli Lilly on the drug ahead of phase 2 testing in autoimmune and inflammatory diseases ...
pharmaphorum3d
After Roche’s exit, Blueprint passes Gavreto on to Rigel
Rigel's chief executive ... and Taiwan), where it has a partnership with CStone Pharmaceuticals. Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar ...